Cross-Sector entity
Children's liquid pain medication is most often covered alongside FDA, which appears in 2 of these 2 stories. pharma accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 3 original sources on average.
2 verified stories tracked
Last mentioned: Mar 20, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Children's liquid pain medication is most often covered alongside FDA, which appears in 2 of these 2 stories. pharma accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 3 original sources on average. We currently track 2 Cross-Sector stories that mention Children's liquid pain medication, all published on March 20, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Children's liquid pain medication. Shared-story counts are live from our verified record — not editorial picks.
Public Health Advisory
Health authorities issue guidance for parents on how to identify and return the product.
Retailer Notification
Pharmacies and retailers begin the process of removing affected lots from shelves.
Recall Announcement
Initial reports confirm nearly 90,000 bottles are affected by a safety recall.
A major recall involving nearly 90,000 bottles of children’s liquid pain medication has been launched across North America. The recall highlights critical safety concerns regarding pediatric dosage accuracy and quality control in the over-the-counter pharmaceutical sector.
A major recall affecting approximately 90,000 bottles of children's liquid pain medication has been initiated across North American markets. The move highlights ongoing vulnerabilities in pediatric pharmaceutical manufacturing and potential supply disruptions for essential over-the-counter treatments.
Source: mynorthwest.com · click2houston.com
